Skip to main content
DB

Delve Bio

Delve Bio provides the Delve Detect test, a metagenomic sequencing (mNGS) solution for diagnosing CNS infections like meningitis and encephalitis. This culture-independent test rapidly identifies bacteria, viruses, fungi, and parasites from cerebrospinal fluid using a comprehensive genetic database. The service offers a higher diagnostic yield and faster turnaround time compared to conventional infectious disease testing methods.

Boston, United StatesFounded 2022327K+ followers
Updated 20 months ago

Funding

$35.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

X
Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional methods for diagnosing central nervous system (CNS) infections often involve a series of individual tests, which can be slow, inefficient, and may not identify all possible pathogens. This can lead to delays in treatment and potentially worse outcomes for patients with serious neurological infections.

Solution

Delve Bio offers Delve Detect, a metagenomic next-generation sequencing (mNGS) test designed for rapid and comprehensive pathogen identification in cerebrospinal fluid (CSF) samples. The test utilizes a single sample to detect a broad range of pathogens, including bacteria, viruses, fungi, and parasites, within two days of sample receipt. Delve Detect employs Delve Decide, a proprietary curated pathogen database, bioinformatic pipeline, and clinical interpretation software, to analyze millions of sequences against a database of over 68,000 unique species. This approach aims to replace the conventional "test-after-test" cycle with a single, comprehensive diagnostic solution, providing clinicians with actionable insights for timely and targeted treatment.

Target Audience

The primary target audience includes clinical laboratories, hospitals, and medical professionals specializing in neurology and infectious diseases who require rapid and comprehensive diagnostic tools for CNS infections.

Features

  • Metagenomic next-generation sequencing (mNGS) for broad, agnostic detection of pathogens
  • Identifies bacteria, viruses, fungi, and parasites from a single CSF sample
  • Rapid turnaround time: results available 2 days after sample arrives at the lab
  • Delve Decide: proprietary curated pathogen database, bioinformatic pipeline, and clinical interpretation software
  • Samples both DNA and RNA
  • Detects viral subtypes directly from original sequence data
  • Streamlined order process with free sample kit and prepaid shipping
This profile is AI-generated and may contain inaccuracies.